BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16516125)

  • 21. Mismatch of minor histocompatibility antigen contributes to a graft-versus-leukemia effect rather than to acute GVHD, resulting in long-term survival after HLA-identical stem cell transplantation in Japan.
    Katagiri T; Shiobara S; Nakao S; Wakano M; Muranaka E; Kuba N; Furukawa T; Tsukada J; Takeda H; Aizawa Y; Harada M
    Bone Marrow Transplant; 2006 Nov; 38(10):681-6. PubMed ID: 16980988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cellular immunotherapy for multiple myeloma.
    Rosenblatt J; Avigan D
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):559-77. PubMed ID: 18790455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Autologous versus allogeneic stem cell transplantation in adult patients with acute lymphoblastic leukemia].
    Wang GR; Xu Y; Zou DH; Zhao YZ; Wang M; Han MZ; Feng SZ; Yan WW; Qiu LG
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Aug; 28(4):544-8. PubMed ID: 16995310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia.
    Anagnostopoulos A; Hari PN; Pérez WS; Ballen K; Bashey A; Bredeson CN; Freytes CO; Gale RP; Gertz MA; Gibson J; Goldschmidt H; Lazarus HM; McCarthy PL; Reece DE; Vesole DH; Giralt SA
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):845-54. PubMed ID: 16864055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peptide vaccines for patients with acute myeloid leukemia.
    Schmitt M; Casalegno-Garduño R; Xu X; Schmitt A
    Expert Rev Vaccines; 2009 Oct; 8(10):1415-25. PubMed ID: 19803762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Umbilical cord graft-versus-leukemia effect induces remission without the price of graft-versus-host disease: the possible role of NK cells.
    Aljitawi OS; Coats A; Zhang D; Ganguly S; Abhyankar S; Lin T; McGuirk JP
    Clin Transplant; 2012; 26(5):663-4. PubMed ID: 22938188
    [No Abstract]   [Full Text] [Related]  

  • 28. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
    Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
    Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma.
    Claviez A; Sureda A; Schmitz N
    Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S16-24. PubMed ID: 18978738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Donor lymphocyte infusions for acute myeloid leukaemia.
    Soiffer RJ
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):455-66. PubMed ID: 18790449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapy.
    Choi BH; Kang HK; Park JS; Kim SK; Pham TN; Zhu XW; Cho D; Nam JH; Chung IJ; Kim YJ; Rhee JH; Kim HJ; Lee JJ
    J Clin Apher; 2006 Dec; 21(4):233-40. PubMed ID: 17120232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second allogeneic stem cell transplantation in myeloid malignancies.
    Hartwig M; Ocheni S; Asenova S; Wiedemann B; Zabelina T; Ayuk F; Kabisch H; Erttmann R; Kröger N; Zander AR; Bacher U
    Acta Haematol; 2009; 122(4):185-92. PubMed ID: 19887774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review.
    Oliansky DM; Rizzo JD; Aplan PD; Arceci RJ; Leone L; Ravindranath Y; Sanders JE; Smith FO; Wilmot F; McCarthy PL; Hahn T
    Biol Blood Marrow Transplant; 2007 Jan; 13(1):1-25. PubMed ID: 17222748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experimental and clinical approaches for optimization of the graft-versus-leukemia effect.
    Sprangers B; Van Wijmeersch B; Fevery S; Waer M; Billiau AD
    Nat Clin Pract Oncol; 2007 Jul; 4(7):404-14. PubMed ID: 17597705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maintenance immunotherapy by repetitive low-dose donor lymphocytes infusions in a child with relapse state aml after allogeneic stem cell transplantation.
    Hartwig M; Weigel S; Bernig T; Bader P; Dölken R; Beck J
    Pediatr Hematol Oncol; 2007 Mar; 24(2):137-40. PubMed ID: 17454780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
    Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
    Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modifying the biological response to acute myeloid leukemia I. BCG, allogeneic leukemic cells and spontaneous cytotoxicity.
    Arends-Merino A; Sjögren AM; Reizenstein P
    Anticancer Res; 1983; 3(4):239-41. PubMed ID: 6576728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
    Maurillo L; Buccisano F; Del Principe MI; Del Poeta G; Spagnoli A; Panetta P; Ammatuna E; Neri B; Ottaviani L; Sarlo C; Venditti D; Quaresima M; Cerretti R; Rizzo M; de Fabritiis P; Lo Coco F; Arcese W; Amadori S; Venditti A
    J Clin Oncol; 2008 Oct; 26(30):4944-51. PubMed ID: 18606980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.
    Greiner J; Döhner H; Schmitt M
    Haematologica; 2006 Dec; 91(12):1653-61. PubMed ID: 17145602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.